Oral chronic graft-versus-host disease: Report from the International Consensus Conference on clinical practice in cGVHD

Clinical Oral Investigations

Volumn 15, Issue 2, 2011, Pages 127-139

  Meier, Johannes K H ^a   Wolff, Daniel ^a   Pavletic, Steve ^b   Greinix, Hildegard ^c   Gosau, Martin ^a   Bertz, Hartmut ^d   Lee, Stefanie J ^e   Lawitschka, Ánita ^f   Elad, Sharon ^g  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF FREIBURG   (Germany)

^e Fred Hutchinson Cancer Research Center   (United States)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Diagnosis; Oral cGVHD; Topical Treatment

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

BONE NECROSIS; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; CONSENSUS DEVELOPMENT; DENTAL CARIES; EVIDENCE BASED DENTISTRY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; JAW DISEASE; MOUTH DISEASE; MOUTH TUMOR; ORAL SURGERY; PERIODONTAL DISEASE; PRACTICE GUIDELINE; REVIEW; SECOND CANCER; TOPICAL DRUG ADMINISTRATION; XEROSTOMIA;

ADMINISTRATION, TOPICAL; CHRONIC DISEASE; DENTAL CARIES; EVIDENCE-BASED DENTISTRY; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAW DISEASES; MOUTH DISEASES; MOUTH NEOPLASMS; NEOPLASMS, SECOND PRIMARY; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; PERIODONTAL DISEASES; XEROSTOMIA;

EID: 79952699996     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-010-0450-6     Document Type: Review

References (88)

1. Couriel D, Carpenter PA, Cutler C et al (2006) Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12(4): 375-396.
2. Baird K, Pavletic SZ (2006) Chronic graft versus host disease. Curr Opin Hematol 13: 426-435.
3. Schubert MM, Correa ME (2008) Oral graft-versus-host disease. Dent Clin North Am 52(1): 79-109.
4. Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12): 945-956.
5. Sullivan KM (2004) Graft vs. host disease. In: Blume KG, Forman SJ, Appelbaum FR (eds) Thomas' hematopoietic cell transplantation, 3rd edn. Blackwell, Malden, pp 635-664.
6. Ferrara JL, Reddy P (2006) Pathophysiology of graft-versus host disease. Semin Hematol 43: 3-10.
7. Martin RW 3rd, Farmer ER, Altomonte VL et al (1995) Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient. Arch Dermatol 131: 333-335.
8. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versus-host disease. Lancet 373(9674): 1550-1561.
9. Imanguli MM, Swaim WD, League SC et al (2009) Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 113(15): 3620-3630.
10. Flowers ME, Parker PM, Johnston LJ et al (2002) Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 100(2): 415-419.
11. Woo SB, Lee SJ, Schubert MM (1997) Graft-vs.-host disease. Crit Rev Oral Biol Med 8: 201-216.
12. Schubert MM, Sullivan KM, Morton TH et al (1984) Oral manifestations of chronic graft-versus-host disease. Arch Intern Med 144: 1591-1595.
13. Schubert MM, Sullivan KM (1990) Recognition, incidence, and management of oral graft-versus host disease. NCI Monogr 9: 135-143.
14. Fox PC, van der Ven P, Sonies BC, Weiffenbach JM, Baum BJ (1985) Xerostomia: evaluation of a symptom with increasing significance. J Am Dent Assoc 110: 519-525.
15. Porter SR, Scully C, Hegarty AM (2004) An update on the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 97: 28.
16. da Fonseca MA, Murdoch-Kinch CA (2007) Severe gingival recession and early loss of teeth in a child with chronic graft versus host disease: a case report. Spec Care Dentist 27(2): 59-63.
17. Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB (1977) Scleroderma, Sjögren's-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 87: 707-709.
18. Curtis RE, Rowlings PA, Deeg HJ et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336(13): 897-904.
19. Demarosi F, Lodi G, Carrassi A et al (2005) Oral malignancies following HSCT: graft versus host disease and other risk factors. Oral Oncol 41(9): 865-877.
20. Otsubo H, Yokoe H, Miya T et al (1997) Gingival squamous cell carcinoma in a patient with chronic graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 84(2): 171-174.
21. Treister NS, Woo SB, O'Holleran EW, Lehmann LE, Parsons SK, Guinan EC (2005) Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(9): 721-731.
22. Pavletic SZ, Martin P, Lee SJ et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 12(3): 252-266.
23. Elad S, Zeevi I, Or R et al (2010) Validation of the National Institute of Health (NIH) Scale for oral chronic graft versus host disease (cGVHD). Biol Blood Marrow Transplant 16(1): 62-69, Epub 2009 Sep 3.
24. Treister N, Stevenson K, Kim H (2009) Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant 16(1): 108-114, Epub 2009 Sep 17.
25. Imanguli MM, Pavletic SZ, Guadagnini JP et al (2006) Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(2): 175-183.
26. Wolff D, Gerbitz A, Ayuk F et al. (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. doi: 10. 1016/j. bbmt. 2010. 06. 015.
27. Elad S, Or R, Garfunkel AA, Shapira MY (2003) Budesonide: a novel treatment for oral chronic graft versus host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 95(3): 308-311.
28. Sari I, Altuntas F, Kocyigit I et al (2007) The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82(5): 349-356.
29. Dilger K, Halter J, Bertz H et al (2009) Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 15(3): 336-343.
30. Wolff D, Anders V, Corio R et al (2004) Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-vs.-host disease. Photodermatol Photoimmunol Photomed 20: 184-9059.
31. National Cancer Institute (2009) Graft-versus-host disease. www. cancer. gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional /page10.
32. França CM, Domingues-Martins M, Volpe A, Pallotta Filho RS, SoaresdeAraújo N (2001) Severe oral manifestations of chronic graft-vs.-host disease. J Am Dent Assoc 132(8): 1124-1127.
33. Eckardt A, Starke O, Stadler M et al (2004) Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40(8): 811-814.
34. Fricain JC, Sibaud V, Swetyenga N, Tabrizi R, Campana F, Taieb A (2007) Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 156(3): 588-590.
35. Albert MH, Becker B, Schuster FR et al (2007) Oral graft vs. host disease in children-treatment with topical tacrolimus ointment. Pediatr Transplant 11(3): 306-311.
36. Sánchez AR, Sheridan PJ, Rogers RS (2004) Successful treatment of oral lichen planus-like chronic graft-versus-host disease with topical tacrolimus: a case report. J Periodontol 75(4): 613-619.
37. Conrotto D, Carrozzo M, Ubertalli AV et al (2006) Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 27; 82(8): 1113-1115, Erratum in: Transplantation. 2007. 83(1): 76.
38. Schlaak M, Treudler R, Colsman A, Al-Ali H, Simon JC (2008) Oral graft-versus-host disease: successful therapy with extracorporeal photopheresis and topical tacrolimus. J Eur Acad Dermatol Venereol 22(1): 112-113.
39. Epstein JB, Reece DE (1994) Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. Bone Marrow Transplant 13(1): 81-86.
40. Epstein JB, Truelove EL (1996) Topical cyclosporine in a bioadhesive for treatment of oral lichenoid mucosal reactions: an open label clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 82(5): 532-536.
41. Deeg HJ, Socié G, Schoch G et al (1996) Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 87(1): 386-392.
42. Menillo SA, Goldberg SL, McKiernan P, Pecora AL (2001) Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation. Bone Marrow Transplant 28(8): 807-808.
43. Redding SW, Callander NS, Haveman CW, Leonard DL (1998) Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 86(2): 183-187.
44. Atkinson K, Weller P, Ryman W, Biggs J (1986) PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1(2): 227-236.
45. Elad S, Garfunkel AA, Enk CD et al (1999) Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88(4): 444-450.
46. Chor A et al (2004) Successful treatment of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic immunosuppression. Eur J Haematol 72: 222-224.
47. Greinix HT, Volc-Platzer B, Rabitsch W et al (1998) Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92(9): 3098-3104.
48. Mawardi H, Stevenson K, Gokani B et al (2009) Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant 45: 1062-1067.
49. Epstein JB, Gorsky M, Epstein MS, Nantel S (2001) Topical azathioprine in the treatment of immune-mediated chronic oral inflammatory conditions: a series of cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91(1): 56-61.
50. Sullivan KM, Witherspoon RP, Storb R et al (1988) Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72(2): 546-554.
51. Curtis RE, Metayer C, Rizzo JD et al (2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105(10): 3802-3811.
52. Yamashita S, Sato S, Kakiuchi Y et al (2002) Lidocaine toxicity during frequent viscous lidocaine use for painful tongue ulcer. J Pain Symptom Manage 24(5): 543-545.
53. Elad S, Cohen G, Zylber-Katz E et al (1999) Systemic absorption of lidocaine after topical application for the treatment of oral mucositis in bone marrow transplantation patients. J Oral Pathol Med 28(4): 170-172.
54. Nozaki-Taguchi N, Shutoh M, Shimoyama N (2008) Potential utility of peripherally applied loperamide in oral chronic graft-versus-host disease related pain. Jpn J Clin Oncol 38(12): 857-860.
55. Elad S, Or R, Shapira MY et al (2003) CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 32(10): 1031-1034.
56. Singhal S, Powles R, Treleaven J et al (1997) Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 24(5-6): 539-543.
57. Nagler RM, Nagler A (2001) The effect of pilocarpine on salivary constituents in patients with chronic graft-versus-host disease. Arch Oral Biol 46(8): 689-695.
58. Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L et al (2007) Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 39: 431-434.
59. Grisius MM (2001) Salivary gland dysfunction: a review of systemic therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 92: 156-162.
60. Fife RS, Chase WF, Dore RK et al (2002) Cevimeline for the treatment of xerostomia in patients with Sjögren's syndrome: a randomized trial. Arch Int Med 162: 1293-1300.
61. Petrone D, Condemi JJ, Fife R et al (2002) A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46(3): 748-754.
62. Yasuda H, Niki H (2002) Review of the pharmacological properties and clinical usefulness of muscarinic agonists for xerostomia in patients with Sjögren's Syndrome. Clin Drug Invest 22(2): 67-73.
63. Carpenter PA, Schubert MM, Flowers ME (2006) Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 12(7): 792-794.
64. Hahnel S, Behr M, Handel G, Bürgers R (2009) Saliva substitutes for the treatment of radiation-induced xerostomia-a review. Support Care Cancer J 17(11): 1331-1343.
65. Majorana A, Schubert MM, Porta F et al (2000) Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Support Care Cancer 8(5): 353-365.
66. Strietzel FP, Martín-Granizo R, Fedele S et al (2007) Electrostimulating device in the management of xerostomia. Oral Dis 13(2): 206-213.
67. Pines M et al (2003) Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 9(7): 417-425.
68. Dahllöf G, Jönsson A, Ulmner M, Huggare J (2001) Orthodontic treatment in long-term survivors after pediatric bone marrow transplantation. Am J Orthod Dentofacial Orthop 120(5): 459-465.
69. van der Pas-van Voskuilen IG, Veerkamp JS, Raber-Durlacher JE, Bresters D, van Wijk AJ, Barasch A, McNeal S, Gortzak RA (2009) Long-term adverse effects of hematopoietic stem cell transplantation on dental development in children. Support Care Cancer 17(9): 1169-1175.
70. American Academy on Pediatric Dentistry Clinical Affairs Committee, American Academy on Pediatric Dentistry Council on Clinical Affairs (2008-2009) Guideline on dental management of pediatric patients receving chemotherapy, hematopoietic cell transplantation, and/or radiation. Pediatr Dent 30(7 Suppl): 219-225.
71. Brennan MT, Woo SB, Lockhart PB (2008) Dental treatment planning and management in the patient who has cancer. Dent Clin North Am 52(1): 19-37.
72. Wilson W, Taubert KA, Gewitz M et al (2007) Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. J Am Dent Assoc 138(6): 739-745, 747-760.
73. Little JW, Falace DA, Miller CS, Rhodus NL (2008) Dental management of the medically compromised patient, 7th edn. Mosby Elsevier, St. Louis.
74. Ruggiero SL, Drew SJ (2007) Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86: 1013-1021.
75. Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587.
76. Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353: 99-102.
77. Hoff AO, Toth BB, Altundag K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23: 826-836.
78. Terpos E, Sezer O, Croucher PI et al (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 20: 1303-1317.
79. Boonyapakorn T, Schirmer I, Reichart PA et al (2008) Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44(9): 857-869.
80. Ruggiero SL, Dodson TB, Assael LA et al (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 67: 2-12.
81. Groetz et al (2006) The guidelines of the German society of dentistry and oral medicine (DGZMK). Dtsch Zahnarztl Z 61: 510-513.
82. Scully C, Madrid C, Bagan J (2006) Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 15(3): 212-218.
83. Montefusco V, Gay F, Spina F et al (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49(11): 2156-2162.
84. Colella G, Campisi G, Fusco V et al (2009) American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67(12): 2698-2699.
85. Leisenring W, Friedman DL, Flowers ME (2006) Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 24(7): 1119-1126.
86. Trullenque-Eriksson A, Muñoz-Corcuera M, Campo-Trapero J et al (2009) Analysis of new diagnostic methods in suspicious lesions of the oral mucosa. Med Oral Patol Oral Cir Bucal 14(5): E210-E216.
87. Mehrotra R, Hullmann M, Smeets R et al (2009) Oral cytology revisited. J Oral Pathol Med 38(2): 161-166.
88. Patton LL, Epstein JB, Kerr AR (2008) Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature. J Am Dent Assoc 139(7): 896-905.